| Arizona Medical & Injury, Pllc | |
|
3655 W Anthem Way, A109 Box 272, Anthem, AZ 85086-0430 | |
| (602) 395-0718 | |
| (602) 343-7973 |
| Full Name | Arizona Medical & Injury, Pllc |
|---|---|
| Type | Facility |
| Speciality | Pain Medicine - Pain Medicine |
| Location | 3655 W Anthem Way, Anthem, Arizona |
| Accepts Medicare Assignments | Does not participate in Medicare Program. The facility may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1215335989 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 111N00000X | Chiropractor | 7346 (Arizona) | Secondary |
| 208VP0000X | Pain Medicine - Pain Medicine | 7346 (Arizona) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Arizona Medical & Injury, Pllc 3655 W Anthem Way, A109 Box 272, Anthem, AZ 85086-0430 Ph: (602) 395-0718 | Arizona Medical & Injury, Pllc 3655 W Anthem Way, A109 Box 272, Anthem, AZ 85086-0430 Ph: (602) 395-0718 |
News Archive
Just as fly paper captures insects, an innovative new device with nano-sized features developed by researchers at UCLA is able to grab cancer cells in the blood that have broken off from a tumor.
Ahead of World Tuberculosis (TB) Day on March 24, three non-governmental organizations (NGOs) released a joint statement warning that "[a] $1.7 billion funding shortfall to fight [TB] over the next five years means 3.4 million patients will go untreated and gains made against the disease will be reversed," Reuters reports.
Researchers at Northwestern University and Washington University School of Medicine have developed the first example of a bioelectronic medicine: an implantable, biodegradable wireless device that speeds nerve regeneration and improves the healing of a damaged nerve.
CombinatoRx, Incorporated and Neuromed Pharmaceuticals Inc., a privately-held biopharmaceutical company, today announced that on November 13, 2009, representatives of Neuromed discussed the pending New Drug Application (NDA) for the product candidate EXALGOTM (hydromorphone HCl extended release) tablets, seeking FDA approval for the management of moderate to severe pain in opioid tolerant patients requiring continuous, around-the-clock opioid analgesia for an extended period of time, with staff from the United States Food and Drug Administration (FDA).
Cancer is driven by numerous genetic and epigenetic changes occurring at the cellular level. These changes drive normal cells to proliferate and escape processes that usually regulate their survival and migration.
› Verified 5 days ago